Compare Estee Lauder Companies Inc (EL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs TransMedics Group Inc — how do they compare? Estee Lauder Companies Inc trades at $82.67 (market cap $29.78B), while TransMedics Group Inc trades at $76.82 (market cap $2.61B). The key difference: Estee Lauder Companies Inc is far larger — about 11.4× TransMedics Group Inc's market cap, and Estee Lauder Companies Inc pays a 1.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| EL | TMDX | |
|---|---|---|
Market Cap | $29.78B | $2.61B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $150.42 |
52-Week Low | $67.23 | $61.99 |
Enterprise Value | $35.95B | $3.01B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $82.72, up 2.3% with recent earnings beats but faces fundamental challenges including a negative net income margin of -1.67% and elevated P/E ratio of 147.8. Technical indicators show bearish momentum with support at $81 and resistance at $84. The company maintains strong gross margins at 74.71% and positive analyst sentiment with 44% buy ratings and $90.60 consensus target.
While recent earnings outperformance and strong brand positioning provide upside potential, investors face risks from declining revenue trends, negative profitability, and high valuation multiples. The stock's near-term direction will depend on Q2 2026 earnings delivery and management's ability to restore sustainable growth amid competitive pressures.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
